Bridge Biotherapeutics Inc
Parataxis Korea, Inc., a clinical stage biotech company, engages in the development of therapeutics for the treatment of ulcerative colitis, fibrotic diseases, and cancers worldwide. Its products in pipeline includes BBT-401, a Pellino-1 inhibitor, which is in Phase I clinical trial for the treatment of ulcerative colitis; and BBT-877, an autotaxin inhibitor that is in Phase I clinical trial for … Read more
Market Cap & Net Worth: Bridge Biotherapeutics Inc (288330)
Bridge Biotherapeutics Inc (KQ:288330) has a market capitalization of $46.07 Million (₩67.45 Billion) as of March 19, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #25286 globally and #1542 in its home market, demonstrating a 3.77% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Bridge Biotherapeutics Inc's stock price ₩770.00 by its total outstanding shares 87602570 (87.60 Million).
Bridge Biotherapeutics Inc Market Cap History: 2019 to 2026
Bridge Biotherapeutics Inc's market capitalization history from 2019 to 2026. Data shows change from $831.51 Million to $46.07 Million (-36.51% CAGR).
Index Memberships
Bridge Biotherapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$167.61 Billion | 0.01% | #798 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$167.61 Billion | 0.01% | #798 of 1384 |
Weight: Bridge Biotherapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Bridge Biotherapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Bridge Biotherapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
103.01x
Bridge Biotherapeutics Inc's market cap is 103.01 times its annual revenue
0.32x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $831.51 Million | $58.28 Billion | $1.32 Billion | 0.01x | 0.63x |
| 2020 | $632.33 Million | $6.34 Billion | -$19.23 Billion | 0.10x | N/A |
| 2021 | $617.11 Million | $1.92 Billion | -$26.28 Billion | 0.32x | N/A |
| 2022 | $504.12 Million | $3.02 Billion | -$41.70 Billion | 0.17x | N/A |
| 2023 | $142.76 Million | $100.00 Million | -$42.32 Billion | 1.43x | N/A |
| 2024 | $224.36 Million | $2.18 Million | -$19.76 Billion | 103.01x | N/A |
Competitor Companies of 288330 by Market Capitalization
Companies near Bridge Biotherapeutics Inc in the global market cap rankings as of March 19, 2026.
Key companies related to Bridge Biotherapeutics Inc by market ranking:
- Goldman Sachs Group Inc (NYSE:GS): Ranked #61 globally with a market cap of $236.20 Billion USD.
- Morgan Stanley (NYSE:MS): Ranked #77 globally with a market cap of $190.97 Billion USD.
- Charles Schwab Corp (NYSE:SCHW): Ranked #109 globally with a market cap of $156.04 Billion USD.
- The Charles Schwab Corporation (MX:SCHW): Ranked #136 globally with a market cap of $136.01 Billion USD ( MX$2.80 Trillion MXN).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #61 | Goldman Sachs Group Inc | NYSE:GS | $236.20 Billion | $805.48 |
| #77 | Morgan Stanley | NYSE:MS | $190.97 Billion | $158.93 |
| #109 | Charles Schwab Corp | NYSE:SCHW | $156.04 Billion | $93.28 |
| #136 | The Charles Schwab Corporation | MX:SCHW | $136.01 Billion | MX$1675.00 |
Bridge Biotherapeutics Inc Historical Marketcap From 2019 to 2026
Between 2019 and today, Bridge Biotherapeutics Inc's market cap moved from $831.51 Million to $ 46.07 Million, with a yearly change of -36.51%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩46.07 Million | -14.06% |
| 2025 | ₩53.61 Million | -76.11% |
| 2024 | ₩224.36 Million | +57.16% |
| 2023 | ₩142.76 Million | -71.68% |
| 2022 | ₩504.12 Million | -18.31% |
| 2021 | ₩617.11 Million | -2.41% |
| 2020 | ₩632.33 Million | -23.95% |
| 2019 | ₩831.51 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of Bridge Biotherapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $46.07 Million USD |
| MoneyControl | $46.07 Million USD |
| MarketWatch | $46.07 Million USD |
| marketcap.company | $46.07 Million USD |
| Reuters | $46.07 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.